flecainide acetate

Phase 2Small molecule

EEastern Cooperative Oncology Group

flecainide acetate is one of 77 small molecule programs targeting Neuropathic Pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

Catecholaminergic Polymorphic Ventricular TachycardiaActive, not recruiting

Atrial FibrillationActive, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

Catecholaminergic Polymorphic Ventricular TachycardiaPreclinical

Active, not recruiting

Atrial FibrillationPhase 2

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Calquence

AstraZeneca

Preclinical

1 2

flecainide acetate

EEastern Cooperative Oncology Group

Phase 2

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 10

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

Completed·VVanderbilt University Medical Center·N/A·NCT01117454·14 enrolled

Atrial Fibrillation1 trial

INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

Completed·IInCarda Therapeutics, Inc.·Phase 2·NCT03539302·176 enrolled

Neuropathic Pain1 trial

Flecainide in Treating Patients With Chronic Neuropathic Pain

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00002996·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for flecainide acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — flecainide acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for flecainide acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEastern Cooperative Oncology Group

flecainide acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Catecholaminergic Polymorphic Ventricular Tachycardia1 trial

Atrial Fibrillation1 trial

Neuropathic Pain1 trial

References

Drug Info

Quick Facts

Related News